CVS Health (CVS)
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-10-30
$90.25-0.09%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - Healthcare PlansSnapshot 2026-10-30
Research Workspace
Put CVS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Free cash flow at least $9.5 billion in fiscal 2026: Free cash flow: $5.65B.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskCVS's case rests on strong recent performance and Health Care Benefits margin recovery, despite mixed earnings quality. Revenue growth accelerated from 6.2% in Q1 FY2026 to 7.3% in Q2. Q2 FY2026 non-GAAP EPS beat consensus by 38%. CVS trades at 12× P/E versus a 22× peer median, with expectations modest versus our view. The multiple depends on margin recovery; the segment's bankruptcy liquidation threatens that objective. Free cash flow of $5.65 billion is below the fiscal 2026 goal of at least $9.5 billion. Peer multiples imply a price about 18% above where it trades; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-30. CVS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 27 analysts currently covering CVS (as of Oct 2026).
Based on 13 Wall Street analysts offering 12-month price targets for CVS in the last 4 months.
Continue this research
Compare CVS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CVS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put CVS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance Health Care Benefits segment margin recovery
CVS is challenging a potential $2 billion ratings-related hit, supporting Health Care Benefits margin recovery.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $90.25
The last 12 months of price, then the range of analyst 12-month targets from today’s $90.25.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Strengthens CVS's operational partnerships, supporting growth.
Long-term partnership supports revenue stability and growth.
Advances: Maintain revenue guidance of at least $400 billion
Strengthened performance supports revenue guidance of at least $400 billion.
Settlement may impact cash flow from operations.
Threatens: Advance Health Care Benefits segment margin recovery
Bankruptcy liquidation undermines margin recovery objectives.
Increase cash flow from operations
Cash flow concerns indicate potential operational headwinds.
Advances: Advance Health Care Benefits segment margin recovery
New tools enhance Health Care Benefits segment margin recovery.
